Indegene Limited INDGN

Global headlines around oil, war risk and a sliding rupee have hit Indian indices hard. At the same time, the same stress can quietly reshape which stocks benefit from a weaker currency and foreign revenue streams. Investors who only focus on the index moves may miss where earnings profiles could shift. This article unpacks that story and spotlights 3 stocks from our rupee weakness screener that appear positively exposed to the current news flow. The three stocks highlighted below are only a...

Indegene Ltd (NSE:INDGN) posts 39.7% YoY revenue surge to INR10,631 million, crosses 100 active clients, and reaffirms margin recovery to 19%-20% by Q4 FY27.

Significant growth in AI-driven medical writing is fueled by the rising complexity of regulatory documentation, adoption of generative AI, and multilingual content demand. North America leads, but tariffs increase costs for cross-border services. Major players like Indegene and TrialAssure drive innovation. AI in Medical Writing Market AI in Medical Writing Market Dublin, July 01, 2026 (GLOBE NEWSWIRE) -- The "AI in Medical Writing Market Report 2026" has been added to ResearchAndMarkets.com's o

Indegene Ltd (NSE:INDGN) surpasses INR 10,000 million in quarterly revenue for the first time, driven by strategic acquisitions and AI integration, despite facing non-operational challenges.

Doceree, the first AI-powered Operating System for healthcare marketing, today announced the appointment of Paresh Rajpurohit (from Indegene) as Vice President - Corporate Development, strengthening its strategic growth team as the company sharpens its focus on corporate development and mergers and acquisitions. The appointment follows the joining of Andreas Tsitsos a few months ago, reinforcing Doceree's commitment to building a dedicated corporate development function.

Indegene Ltd (NSE:INDGN) reports strong revenue growth and strategic advancements, despite facing short-term profitability challenges.

By John Vandermosten, CFA NASDAQ:CING READ THE FULL CING RESEARCH REPORT Cingulate, Inc. (NASDAQ:CING) reported third quarter 2025 results on November 13 th , 2025. No revenues were recorded and operating expense totaled $6.0 million. The new drug application (NDA) to the FDA was accepted and a PDUFA date of May 31 st , 2026 was given. Cingulate also saw changes in its management ranks as the

Indegene Ltd (NSE:INDGN) reports strong revenue growth and strategic acquisitions, while navigating margin challenges and segmental shifts.